Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | GRK6 | P43250 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5252164 | 0.83 | HDAC1 (0.45) | CYP2A6BRD4CREBBPSMN1; SMN2KDM4E | |
| SCHEMBL11926858 | 0.82 | CYP2A6 (0.62) | CYP2A6BRD4CREBBPSMN1; SMN2KDM4E | |
| SCHEMBL14076589 | 0.79 | SMN1; SMN2 (0.55) | CYP2A6BRD4CREBBPSMN1; SMN2KDM4E | |
| SCHEMBL4457861 | 0.78 | S1PR1 (0.47) | CYP2A6BRD4CREBBPSMN1; SMN2KDM4E | |
| SCHEMBL9454459 | 0.77 | CYP2A6 (0.53) | CYP2A6SMN1; SMN2KDM4EALDH1A1CHRNA7 | |
| SCHEMBL18974765 | 0.77 | KMT2A (0.47) | CYP2A6BRD4CREBBPSMN1; SMN2KDM4E | |
| SCHEMBL23289039 | 0.76 | CYP1A2 (0.42) | CYP2A6SMN1; SMN2KDM4EALDH1A1CYP1A2 | |
| SCHEMBL10154296 | 0.76 | PRMT6 (0.50) | CYP2A6SMN1; SMN2KDM4EALDH1A1CHRNA7 | |
| SCHEMBL5328745 | 0.75 | GRK6 (0.47) | CYP2A6BRD4CREBBPSMN1; SMN2KDM4E | |
| SCHEMBL4948621 | 0.75 | LMNA (0.47) | SMN1; SMN2KDM4EALDH1A1MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114206870-A | Tricyclic AKR1C3 dependent KARS inhibitors | 诺华股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
| US-20190019964-A1 | ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2019-01-17 | — | — | US | disclosed |
| US-7960556-B2 | Thiadiazole derivatives for the treatment of neuro-degenerative diseases | NV REMYND (BE) | 2011-06-14 | — | — | US | disclosed |
| EP-2094677-B1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | REMYND NV (BE) | 2011-01-12 | — | — | EP | disclosed |
| US-20100144709-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | NV REMYND (BE) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190019964-A1 | ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | LEF1, OCIAD1, POU2F1 | CYP2A6 2757/4885BRD4 3758/4885CREBBP 2461/4885 |
| US-20100144709-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | SNCA, PARK7, PRNP | CYP2A6 4301/4885BRD4 224/4885CREBBP 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.